Skip to main content
Journal cover image

Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis.

Publication ,  Journal Article
Shah, R; Latham, SB; Porta, JM; Naz, A; Matin, K; Rao, SV
Published in: Catheter Cardiovasc Interv
August 1, 2019

OBJECTIVES: To evaluate the efficacy of post-primary percutaneous coronary intervention (PCI) bivalirudin infusion (at full PCI dose) to prevent stent thrombosis (ST) compared with heparin monotherapy. BACKGROUND: Early randomized controlled trials (RCTs) have shown that compared with heparin use, bivalirudin use during primary PCI is associated with an increased risk of ST. However, bivalirudin was stopped in those trials at the end of the procedure and glycoprotein IIb/IIIa inhibitors (GPIs) were routinely used with heparin. The increased risk of ST may be eliminated by continuing bivalirudin infusion post-procedure for few hours. Indeed, in most recent trials, a trend of lower ST risk has been observed with a post-procedure infusion of bivalirudin compared with heparin monotherapy (without the routine use of GPI). METHODS: Relevant RCTs were included and risk ratios (RRs) were calculated using random effect models. The primary outcome of interest was the risk of early definite ST. RESULTS: Four RCTs involving 13,505 patients were included in this meta-analysis. Compared with heparin monotherapy, bivalirudin (with a post-procedure infusion) was associated with a 55% decrease in the risk of early definite ST (RR: 0.45, 95% confidence interval: 0.23-0.85; P = 0.015). There was no difference in the risk of early ST between bivalirudin (with a post-procedure infusion) and heparin with GPI. CONCLUSIONS: For primary PCI, a bivalirudin-based anticoagulant strategy (with post procedure infusion) is associated with a lower risk of early definite ST compared with treatment with heparin monotherapy (without GPI).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

August 1, 2019

Volume

94

Issue

2

Start / End Page

210 / 215

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Stents
  • Risk Factors
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Percutaneous Coronary Intervention
  • Peptide Fragments
  • Humans
  • Hirudins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, R., Latham, S. B., Porta, J. M., Naz, A., Matin, K., & Rao, S. V. (2019). Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheter Cardiovasc Interv, 94(2), 210–215. https://doi.org/10.1002/ccd.28065
Shah, Rahman, Samuel B. Latham, Jennifer M. Porta, Arshi Naz, Khalid Matin, and Sunil V. Rao. “Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis.Catheter Cardiovasc Interv 94, no. 2 (August 1, 2019): 210–15. https://doi.org/10.1002/ccd.28065.
Shah R, Latham SB, Porta JM, Naz A, Matin K, Rao SV. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheter Cardiovasc Interv. 2019 Aug 1;94(2):210–5.
Shah, Rahman, et al. “Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis.Catheter Cardiovasc Interv, vol. 94, no. 2, Aug. 2019, pp. 210–15. Pubmed, doi:10.1002/ccd.28065.
Shah R, Latham SB, Porta JM, Naz A, Matin K, Rao SV. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheter Cardiovasc Interv. 2019 Aug 1;94(2):210–215.
Journal cover image

Published In

Catheter Cardiovasc Interv

DOI

EISSN

1522-726X

Publication Date

August 1, 2019

Volume

94

Issue

2

Start / End Page

210 / 215

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Stents
  • Risk Factors
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Percutaneous Coronary Intervention
  • Peptide Fragments
  • Humans
  • Hirudins